Tailored Therapy for Clarithromycin-Resistant H. Pylori

• Status: Unknown status
• Trial end date: 2020-12-30
• Target enrollment: 0
• Participant gender: All

Summary

Clarithromycin-resistant H. pylori is the main cause of H. pylori eradication failure. Tailored therapy on the basis of detection of a clarithromycin resistance mutation by PCR has been studied recently, however, there have been few studies comparing treatment regimen in patient with clarithromycin-resistant H. pylori. We used sequencing-based clarithromycin resistance mutation and aimed to compare PAM (proton pump inhibitor, amoxicilline, metronidazole) regimen and PBMT (proton pump inhibitor, bismuth, metronidazole, tetracyclin) regimen in patient with clarithromycin-resistant H. pylori.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kangdong Sacred Heart Hospital
• Treatments: Bismuth; Clarithromycin

Criteria

Inclusion Criteria:

• peptic ulcer disease

• H. pylori gastritis

• low grade MALT lymphoma

Exclusion Criteria:

• history of gastric cancer surgery

• severe comorbidity (ESRD, LC)

• hypersensitivity to drug

• pregnancy